Japan· JP-4291099M1022
フェドラチニブ塩酸塩水和物
A fedratinib product containing フェドラチニブ塩酸塩水和物, registered in Japan by レコルダティ・レア・ディジーズ・ジャパン, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Fedratinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EJ02 (fedratinib), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Fedratinib · ATC L01EJ02
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- フェドラチニブ塩酸塩水和物
- Manufacturer
- レコルダティ・レア・ディジーズ・ジャパン
- Country
- Japan (JP)
- ATC code
- L01EJ02
- ATC class
- Fedratinib
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
554 interactions on record for fedratinib.
Graded by severity as the source publishes them — 161 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fedratinib · interactions on record
554 records
- 161 severe
- 370 moderate
- 23 minor
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- EliglustatA16AX10severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EJ02
Fedratinib, as other registers publish it.
- United StatesInrebicCelgene Corporation
- IcelandInrebicBristol-Myers Squibb Pharma EEIG*
- NorwayInrebicBristol-Myers Squibb Pharma EEIG
- DenmarkInrebicBristol-Myers Squibb Pharma EEIG
- PolandInrebicBristol-Myers Squibb Pharma EEIG
- United StatesInrebicCelgene Corporation
- FinlandInrebicBristol-Myers Squibb Pharma EEIG
- CzechiaINREBICBristol-Myers Squibb Pharma EEIG, Dublin
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dd57dc3b-2070-4986-bfe2-f043a0848d90 GET /v1/drugs/dd57dc3b-2070-4986-bfe2-f043a0848d90?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１００ｍｇ１カプセル",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291099M1022",
"category": "内用薬",
"price_yen": 9567,
"generic_name": "フェドラチニブ塩酸塩水和物",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": "9567"
}See everything about fedratinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.